Patent Application
20210128730
The invention relates to methods for treating tumors. In particular, the invention provides novel use of nanoparticles in combination with ionizing radiations for treating tumors, wherein the combined effect of nanoparticles induces senescence and/or cannibalism of the tumor cells.
The radiation therapy (also known as radiotherapy) is one of the most used anti-tumor strategies. More than half of all patients with cancer are treated with ionizing radiation (IR) alone or in combination with surgery or chemotherapy.1 Recent progresses realized in medical physics (with the development of low/high energy radiation, the implementation of mono-, hypo- or hyper-fractionation schedule and the diversification of dose rates used) and the development of innovative medical technologies (such as the 3D-conformational radiotherapy (3D-CRT), the intensity modulated radiation therapy (IMRT), the stereotactic radiosurgery (SRS) and the functional imaging)) contribute to better deliver the efficient doses of radiation on tumors whilst sparing surrounding healthy tissues, which is the most usual side effect of radiation therapy.2 Several applications of nanomedecine (such as radioisotope-labeled or metallic nanoparticles) have been developed to improve this therapeutic index by using nanomaterials as imaging or contrast agents to better deliver the radiation doses into tumor sites and/or as radiosensitizers, to enhance the dose deposition in tumors and reduce irradiation-related side-effects.3,4,5,6,7 Considering that the radiation dose absorbed by any tissues is related to the square of relative atomic number (Z2) of the material (where Z is the atomic number)8, nanoparticles containing high-Z atoms (such as gold or gadolinium) have been extensively investigated for their potential to improve radiotherapy. Under exposure to ionizing radiations, heavy-metal based nanoparticles produce photons and Auger electrons that improve the total dose rate deposition into the tumors, induce the production of reactive oxygen species (ROS) and cause cellular damages on many tumors (including for example melanoma, glioblastoma, breast and lung carcinomas).9, 10, 11 Despite the fact that several preclinical animal models revealed the ability of the combination of heavy-metal based nanoparticles with ionizing radiation to reduce tumor growth, there is still a need to improve the use of nanoparticles in anti-cancer treatments in combination with ionizing radiations. In this the present disclosure, the inventors explored the ability of the combination of high-Z element containing nanoparticles, and in particular gadolinium-based nanoparticles (GdBN), with ionizing radiation to induce both cellular senescence and the death through non-cell-autonomous mechanisms. The inventors revealed that the irradiation of cancer cells in presence of GdBN enhances the ability of irradiated cancer cells to undergo senescence. In parallel, they observed that irradiated cancer cells also exhibit cannibalistic activity and eliminate after live cell engulfment, both irradiated and non-irradiated neighboring cancer cells. They further deciphered signaling pathways that are involved in the biological effects elicited by the irradiation of cancer cells in presence of GdBN and revealed that after an irradiation in presence of GdBN, the proliferation of cancer cells may be impaired by both senescence and cellular cannibalism inductions, said inductions being mediated by NOX5 and ROCK1 activity. These findings opened new insights for optimized anti-cancer treatments combining nanoparticles and ionizing radiations.
A first aspect of the present disclosure relates to a method of treating a tumor in a subject in need thereof, the method comprising
wherein the combined effect of the ionizing radiations and the nanoparticles induce senescence and/or cellular cannibalism to the irradiated tumor cells.
In specific embodiments, said tumor is exposed to a dose per fraction of ionizing radiations of at least 3 Gy, and for example between 3 Gy and 9 Gy, or between 5 and 7 Gy. In a more specific embodiment of the previous embodiment, the total dose of ionizing radiations is administered in no more than 10 fractions, for example within 3 to 8 consecutive weeks. In one specific embodiment, the method further includes a step of determining NOX5 and/or ROCK1 expression level or activity in the tumor, prior to the treatment step. Typically, the subject to be treated is selected among the subjects having a tumor wherein NOX5 and/or ROCK1 activity or expression level higher than or at least substantially the same as a control value.
In specific embodiments, the method further comprises a step of administering an enhancer or a modulator agent of NOX5 and/or ROCK1 activity, prior to, or concomitantly, or after the exposure step to ionizing radiations, for increasing NOX5 and/or ROCK1 activity in the tumor.
In preferred embodiments, the combined effect of the ionizing radiations and the nanoparticles induces an immune response mediated by NOX5 activity, against the tumor cells.
In specific embodiments, the method further comprises a step of administering a immunotherapeutic agent prior to, or concomitantly, or after the exposure step to ionizing radiations, in order to further enhance an immune response against the tumor cells in addition or synergy to the immune response induced by the combined effect of ionizing radiations and nanoparticles. Typically, said immunotherapeutic agent may be selected among the immune checkpoint inhibitors, such as PD1/PDLL inhibitors, CTLA4 inhibitors.
In a specific embodiment, the subject to be treated is selected among the subjects having a tumor resistant to a chemotherapeutic treatment inducing apoptosis.
In specific embodiments, the method further comprises a step of administering a senescence inducer agent in tumor cells, which further enhances senescence in tumor cells, in addition or synergy to the senescence induced by the combined effect of the ionizing radiations and the nanoparticles. Typically, a sublethal dose of a chemotherapeutic agent may be administered as a senescence inducer agent.
In the above method of treatment, non-irradiated cells may be further killed by cellular cannibalism of neighboring irradiated cells.
In specific embodiments, senescence is enhanced by a factor of at least 10%, 20%, 30%, 40% or at least 50%, as compared to senescence induced by the same exposure to ionizing radiations but without the presence of nanoparticles.
Similarly, in specific embodiments, cellular cannibalism is enhanced by a factor of at least 10%, 20%, 30%, 40% or at least 50%, as compared to cellular cannibalism induced by the same exposure to ionizing radiations but without the presence of nanoparticles.
In specific embodiment, the volume of the tumors exposed to the ionizing radiations is smaller than the total volume of the tumor to be treated, for example at least 10% smaller (in volume), or at least 20% smaller (in volume), or at least 30% smaller (in volume), or at least 40% smaller (in volume), or at least 50% smaller (in volume).
The method may further enable the treatment of tumors located outside of the region exposed to the ionizing radiations.
In preferred embodiments, said ionizing radiations are X-ray or y-ray radiations.
In preferred embodiments, said nanoparticle comprises a rare earth metal, and preferably gadolinium, as a high-Z element. For example, at the time of irradiation, the high-Z element (e.g. gadolinium) concentration in the tumor, may be between 0,1 and 10 μg high-Z element.g−1.
In further preferred embodiments, said nanoparticle comprises chelates of high-Z element, for example rare earth elements.
Typically, said nanoparticle may comprise
In the previous embodiment, said chelates may be advantageously selected from the group consisting of: DOTA, DTPA, DTPABA, DOTAGA. For example, said chelates of rare earth elements are chelates of gadolinium, preferably, DOTAGA chelating Gd3+. More specifically, the ratio of high-Z elements (for example rare earth elements) per nanoparticle, for example the ratio of gadolinium per nanoparticle, may be between 3 and 100, preferably between 5 and 20.
In specific embodiments, the nanoparticle may be administered intravenously. For example, a single dose between 15 mg/kg and 100 mg/kg of nanoparticles may be injected intravenously in a subject.
In specific embodiments, the nanoparticle is present in the irradiated region of the tumor at a concentration comprised between 0,1 mg/l and 1 g/l, preferably between 0,1 and 100 mg/l. Another aspect of the invention relates to a method of inducing senescence and/or cellular cannibalism of tumor cells and/or an immune response against said tumor cells in a subject in need thereof, said method comprising
Another aspect of the invention relates to a suspension of nanoparticles for use in the above defined methods of treatment. In particular, the invention relates to a suspension of nanoparticles for use in a method of treating a tumor in a subject in need thereof, the method comprising
wherein the combined effect of the ionizing radiations and the nanoparticles induce senescence and/or cellular cannibalism to the irradiated tumor cells.
The present invention relates to a method of treating a tumor in a subject in need thereof, the method comprising
As used herein, the term “treat” or “treatment” is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired results can include but not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, reversal of disease, amelioration or palliation of the disease state, and remission (whether partial or total). In particular, with reference to the treatment of a tumor, the term “treatment” may refer to the inhibition of the growth of the tumor, or the reduction of the size of the tumor.
The Nanoparticles Used in the Methods According to the Invention
The present invention follows from the surprising advantages, demonstrated by the inventors, of a combined effect of certain nanoparticles with ionizing radiations to induce senescence and/or cellular cannibalism and/or immune response against the tumor cells.
The advantageous effects of the method of the present invention are linked in particular to two preferred features of the nanoparticles:
They contain high-Z element to act as a radiosensitizing agent, for example an element with an atomiz Z number higher than 40, for example higher than 50. In specific embodiments, said high-Z element is selected among the heavy metals, and more preferably, Au, Ag, Pt, Pd, Sn, Ta, Zr, Tb, Tm, Ce, Dy, Er, Eu, La, Nd, Pr, Lu, Yb, Bi, Hf, Ho, Pm, Sm, In, and Gd, and mixtures thereof.
They have preferably a very small mean hydrodynamic diameter. Nanoparticles with a mean diameter for example of between 1 and 10 nm, and even more preferably between 1 and 5 nm or for example 1 and 5 nm, typically, around 3 nm, allowing an excellent distribution of these nanoparticles in the tumors, and a rapid renal elimination (and therefore low toxicity) will be advantageously selected.
The size distribution of the nanoparticles is, for example, measured using a commercial particle sizer, such as a Malvern Zetasizer Nano-S particle sizer based on PCS (Photon Correlation Spectroscopy). This distribution is characterized by a mean hydrodynamic diameter.
For the purposes of the invention, the term “mean hydrodynamic diameter” or “mean diameter” is intended to mean the harmonic mean of the diameters of the particles. A method for measuring this parameter is also described in standard ISO 13321:1996.
In preferred embodiment, the nanoparticles further comprise in addition to the high-Z element, a biocompatible coating. Agent suitable for such biocompatible includes without limitation biocompatible polymers, such as polyethylene glycol, polyethyleneoxide, polyacrylamide, biopolymers, polysaccharides, or polysiloxane.
The nanoparticles can be advantageously used also as an imaging or a contrast agent, for example, in image-guided radiation therapy. The term “contrast agent” is intended to mean any product or composition used in medical imaging for the purpose of artificially increasing the contrast making it possible to visualize a particular anatomical structure (for example certain tissues or organs) or pathological anatomical structures (for example tumors) with respect to neighboring or non-pathological structures. The term “imaging agent” is intended to mean any product or composition used in medical imaging for the purpose of creating a signal making it possible to visualize a particular anatomical structure (for example certain tissues or organs) or pathological anatomical structures (for example tumors) with respect to neighboring or non-pathological structures. The principle of how the contrast or imaging agent operates depends on the imaging technique used.
Advantageously, it will be possible to combine the use of the nanoparticles in the method of treatment of the invention, and for an in vivo detection by MRI, enabling, for example, monitoring of the therapeutic treatment as disclosed in the present invention.
Preferably, only lanthanides, including at least 50% by weight of gadolinium (Gd), of dysprosium (Dy), of lutetium (Lu), for bismuth (Bi) or of holmium (Ho), or mixtures thereof, for example at least 50% by weight of gadolinium, will be chosen as high-Z element in the nanoparticles.
According to one variant, use will be made of nanoparticles in which the part containing lanthanides contains, at its periphery, lanthanides which cause an MRI signal, for example gadolinium, and at least one high-Z element (e.g. Bi) in its central part. Radiation-absorbing high-Z metals with a very high atomic number may therefore be located at the center of the core of the nanoparticle.
In one particular embodiment, the nanoparticles that can be used according to the invention are characterized in that they comprise at least one contrast agent for T1 MRI imaging, and at least one other imaging or contrast agent suitable for one of the following imaging techniques:
Preferably, the nanoparticles are chosen such that they have a relaxivity r1 per particle of between 50 and 5000 mM−1 s−1 (at 37° C. and 1.4 T) and/or a Gd weight ratio of at least 5%, for example between 5% and 50%.
In one specific embodiment, said nanoparticles with a very small hydrodynamic diameter, for example between 1 and 10 nm, preferably between 1 and 5 nm, are nanoparticles comprising chelates of high-Z elements, for example chelates of rare earth elements, and more preferably chelates of gadolinium or bismuth.
In specific embodiments that may be preferably combined with the previous embodiment, said nanoparticles comprises
In a specific embodiment, that may be preferably combined with the previous embodiment, said chelates are selected from the group consisting of DOTA, DTPA, EDTA, EGTA, BAPTA, NOTA, DOTAGA, and DTPABA, and mixtures thereof.
In a specific embodiment, that may be preferably combined with the previous embodiment, said chelates of rare earth element are chelates of gadolinium and/or bismuth, preferably DTPA or DOTAGA chelating Gd3+ and/or Bi.
In specific and preferred embodiments, the ratio of high-Z element per nanoparticle, for example the ratio of rare earth elements, e.g. gadolinium (optionally as chelated with DOTAGA) per nanoparticle, is between 3 and 100, preferably between 5 and 20, typically around 10.
For imaging by scintigraphy, the nanoparticles may additionally comprise a radioactive isotope that can be used in scintigraphy, and that is preferably chosen from the group consisting of the radioactive isotopes of In, Tc, Ga, Cu, Zr, Y or Lu, for example: 111In, 99mTc, 67Ga, 68Ga, 64Cu, 89Zr, 90Y or 177Lu.
For fluorescence in the near-infrared range, the nanoparticles may additionally comprise a lanthanide chosen from Nd, Yb or Er may.
For fluorescence in the visible range, the nanoparticles may additionally comprise a lanthanide chosen from Eu or Tb can be used.
For fluorescence in the near-infrared range, the nanoparticles may additionally comprise an organic fluorophore chosen from Cyanine 5.5, Cyanine 7, Alexa 680, Alexa 700, Alexa 750, Alexa 790, Bodipy.
In specific embodiments, the hybrid nanoparticles are of core-shell type. Nanoparticles of core-shell type, based on a core consisting of a rare earth oxide and of an optionally functionalized polyorganosiloxane matrix are known (see in particular WO 2005/088314, WO 2009/053644).
The nanoparticles may further be functionalized with molecules which allow targeting of the nanoparticles to specific tissues. Said agents can be coupled to the nanoparticle by covalent couplings, or trapped by non-covalent bonding, for example by encapsulation or hydrophilic/hydrophobic interaction or using a chelating agent.
In one specific embodiment, use is made of hybrid nanoparticles comprising:
where appropriate, a targeting molecule, for the targeting of the nanoparticles, said targeting molecule being grafted to the POS or to the chelates.
In the case of a structure of core-shell type, the POS matrix forms the superficial layer surrounding the metal cation-based core. Its thickness can range from 0.5 to 10 nm, and can represent from 25% to 75% of the total volume.
The POS matrix acts as protection for the core with respect to the external medium (in particular protection against hydrolysis) and it optimizes the properties of the contrast agents (luminescence, for example). It also allows the functionalization of the nanoparticle, via the grafting of chelating agents and of targeting molecules.
Advantageously, the chelate is chosen from the following products:
If M is a lanthanide, e.g. Gd, the chelate is advantageously selected from those which have lanthanide-complexing properties, in particular those of which the complexation constant log(KC1) is greater than 15, preferentially 20. As preferred examples of lanthanide-complexing chelating agents, mention may be made of those comprising a unit of diethylenetriaminepentaacetic acid (DTPA), of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), or of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), or derivatives thereof and 1,4,7,10-tetraazacyclododecane-1,glutaric anhydride-4,7,10-triacetic acid (DOTAGA).
In addition, depending on the intended application, the nanoparticles are optionally doped with another rare earth or actinide metal cation, for example a lanthanide, or even two different lanthanides, at least one being chosen from Eu and Tb.
“Core-Free” Ultrafine Nanoparticles
In one more particularly preferred embodiment, owing in particular to their very small size and rigid structure, the nanoparticles that can be used according to the invention are obtained by a top-down synthesis route comprising the steps of:
These nanoparticles obtained according to the mode described above do not comprise a core of metal oxide encapsulated by at least one coating. More details regarding the synthesis of these nanoparticles are given in the next section.
This top-down synthesis method results in observed sizes typically of between 1 and 5 nm.
The term then used is ultrafine nanoparticles.
These “ultrafine” or “core-free” nanoparticles are optionally grafted to targeting molecules, and in particular molecules targeting lung tissues as described in the following paragraph.
Another characteristic of these ultrafine nanoparticles is the maintaining of the rigid nature of the objects and of the overall geometry of the particles after injection. This strong three-dimensional rigidity is provided by the polysiloxane matrix, where the majority of the silicons are bonded to 3 or 4 other silicon atoms by an oxygen bridge. The combination of this rigidity with their small size makes it possible to increase the relaxivity of these nanoparticles for the intermediate frequencies (20 to 60 MHz) compared with the commercial compounds (Gd-DOTA-based complexes for example), but also for frequencies above 100 MHz present in new-generation high-field MRIs.
Preferably, the nanoparticles for use in the method according to the invention have a relaxivity r1 per Mn+ ion greater than 5 mM−1·s−1 (at 37° C.) (of Mn+ ion), preferentially 10 mM−1·s−1 (at 37° C.) (of Mn+ ion), for a frequency of 20 MHz. For example, they have a relaxivity r1 per nanoparticle of between 50 and 5000 mM−1·s−1. Even better still, these nanoparticles have a relaxivity r1 per Mn+ ion at 60 MHz which is greater than or equal to the relaxivity r1 per Mn+ ion at 20 MHz. The relaxivity r1 considered here is a relaxivity per Mn+ (for example gadolinium) ion. r1 is extracted from the following formula: 1/T1=[1/T1]water+r1[Mn+]. Further details regarding these ultrafine nanoparticles, the processes for synthesizing them and their uses are described in patent application WO 2011/135101, which is incorporated by way of reference.
Process for Obtaining Preferred Embodiments of Nanoparticles for use According to the Invention
Generally, those skilled in the art will be able to easily produce nanoparticles used according to the invention. More specifically, the following elements will be noted:
For nanoparticles of core-shell type, based on a core of lanthanide oxide or oxyhydroxide, use will be made of a production process using an alcohol as solvent, as described for example in P. Perriat et al., J. Coll. Int. Sci, 2004, 273, 191; 0. Tillement et al., J. Am. Chem. Soc., 2007, 129, 5076 and P. Perriat et al., J. Phys. Chem. C, 2009, 113, 4038.
For the POS matrix, several techniques can be used, derived from those initiated by Stoeber (Stoeber, W; J. Colloid Interf Sci 1968, 26, 62). Use may also be made of the process used for coating as described in Louis et al. (Louis et al., 2005, Chemistry of Materials, 17, 1673-1682) or international application WO 2005/088314.
In practice, synthesis of ultrafine nanoparticles is for example described in Mignot et al Chem. Eur. J. 2013, 19, 6122-6136: Typically, a precursor nanoparticle of core/shell type is formed with a lanthanide oxide core (via the modified polyol route) and a polysiloxane shell (via sol/gel); this object has, for example, a hydrodynamic diameter of around 10 nm (preferentially 5 nanometers). A lanthanide oxide core of very small size (adjustable less than 10 nm) can thus be produced in an alcohol by means of one of the processes described in the following publications: P. Perriat et al., J. Coll. Int. Sci, 2004, 273, 191; O. Tillement et al., J. Am. Chem. Soc., 2007, 129, 5076 and P. Perriat et al., J. Phys. Chem. C, 2009, 113, 4038. These cores can be coated with a layer of polysiloxane according to, for example, a protocol described in the following publications: C. Louis et al., Chem. Mat., 2005, 17, 1673 and O. Tillement et al., J. Am. Chem. Soc., 2007, 129, 5076.
Chelating agents specific for the intended metal cations (for example DOTAGA for Gd3+) are grafted to the surface of the polysiloxane; it is also possible to insert a part thereof inside the layer, but the control of the formation of the polysiloxane is complex and simple external grafting gives, at these very small sizes, a sufficient proportion of grafting.
The nanoparticles are separated from the synthesis residues by means of a method of dialysis or of tangential filtration, on a membrane comprising pores of appropriate size.
The core is destroyed by dissolution (for example by modifying the pH or by introducing complexing molecules into the solution). This destruction of the core then allows a scattering of the polysiloxane layer (according to a mechanism of slow corrosion or collapse), which makes it possible to finally obtain a polysiloxane object with a complex morphology, the characteristic dimensions of which are of the order of magnitude of the thickness of the polysiloxane layer, i.e. much smaller than the objects produced up until now.
Removing the core thus makes it possible to decrease from a particle size of approximately 5 nanometers in diameter to a size of approximately 3 nanometers. Furthermore, this operation makes it possible to increase the number of M (e.g. gadolinium) per nm3 in comparison with a theoretical polysiloxane nanoparticle of the same size but comprising M (e.g. gadolinium) only at the surface. The number of M for a nanoparticle size can be evaluated by virtue of the M/Si atomic ratio measured by EDX.
Targeting molecules can be grafted onto these nanoparticles for example using coupling by peptide bonding on an organic constituent of the nanoparticle, as described in Montalbetti, C.A.G.N, Falque B. Tetrahedron 2005, 61, 10827-10852.
Use may also be made of a coupling method using “click chemistry”, Jewett, J.C.; Bertozzi, C.R. Chem. Soc. Rev. 2010, 39, 1272-1279, and involving groups of the type: —N3, —CN or —C≡CH, or one of the following groups:
In one specific embodiment, the nanoparticle according to the invention comprises a chelating agent which has an acid function, for example DOTA or DOTAGA. The acid function of the nanoparticle is activated for example using EDC/NHS (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydrosuccinimide) in the presence of an appropriate amount of targeting molecules. The nanoparticles thus grafted are then purified, for example by tangential filtration.
The subject to be treated
The methods according to the present invention are intended to treat tumor of patients, for example tumor of human patient.
The term “patient” and “subject” which are used herein interchangeably refer to any member of the animal kingdom, preferably a mammal, or a human being, including for example a subject that has a tumor.
In specific embodiments, the method of treatment is directed to the treatment of malignant solid tumors, in particular of brain tumors (primary and secondary, glioblastoma . . . ), pelvic malignancies (cervix, prostate, ano rectal and colorectal cancer), liver cancer (primary and secondary), head and neck cancers, lung cancer, eosophagus cancer, breast cancer, pancreatic cancer.
The inventors have identified that the advantageous induction of cellular cannibalism and/or senescence by the combined effect of the nanoparticles and ionizing radiations is mediated by NOX5 and/or ROCK1 activity. Indeed, when inhibiting NOX5 and/or ROCK1 activity in vitro in tested cancer cell lines, the induction of cellular cannibalism and/or senescence is not observed.
The patient in need of such treatment may thus be advantageously selected among the patients with tumors with high expression level of NOX5 and/or ROCK1 activity. Those patients are predicted to be good responders to the treatment combining the nanoparticles and ionizing radiations, for inducing senescence and/or cellular cannibalism against said tumor cells to be treated.
As used herein, the term “NOX5” refers to the NADPH oxidase 5 and preferably human NOX5, which generates superoxide. Nox5 interacts with c-abl and superoxide production leads to phosphorylation of c-abl, while inhibition of c-abl kinase activity inhibits Nox5 superoxide production. NOX5 has the protein sequence as identified by reference Q96PH1 in UniProtKB.
As used herein, the term “ROCK1” refers to the Rho-associated coil-coil containing protein kinase 1, which is protein serine/threonine kinase that is activated when bound to the GTP-bound form of Rho. ROCK1 has the protein sequence as identified by reference Q13464 in UniProtKB.
When referring to “NOX5 or ROCK1 expression level or activity”, it is referred herein either to, the expression level of the gene (such as mRNA expression) and/or to the corresponding protein expression and/or to the corresponding protein activity (enzymatic activity).
Accordingly, in one preferred embodiment, the method of treatment includes a step of determining NOX5 and/or ROCK1 expression level or activity. A patient is predicted to be a good responder to the treatment of the present invention for example when NOX5 and/or ROCK1 expression level or activity in the tumor of the patient is substantially identical to or higher than a control value.
As used herein, a higher expression level or activity means a statistically significant increase of such expression level or activity as compared to a control value, preferably, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% increase of the control value.
The term “good responder” as used herein means that the patient is likely to benefit of a better response to the treatment as compared to a patient with expression level or activity of NOX5 and/or ROCK1 corresponding, for example, to a control value.
The methods of the invention thus comprises the step of (a) determining the expression of NOX5 and/or ROCK1 as predictive biomarkers, in a biopsy or tumor cells obtained from the tumor of said patient and (b) comparing the obtained expression values to corresponding control values.
Said control value may be for example, the mean value of normalized (relative) mean value of NOX5 and/or ROCK1 expression in corresponding tumors of responder patients and/or low-responder patients.
Said control value can also be determined by routine experimentation depending on the quantification methods and the predictive biomarkers that will be used for the methods of the invention.
For example, said control value corresponds to the expression level value observed for low-responder patients, and a patient is predicted to be a responder when the expression level value is statistically higher than the control value.
Alternatively, said control value corresponds to the expression level value observed for responder patients, and a patient is predicted to be a responder when the expression level value is statistically not different or even higher from the control value (threshold value).
Further alternatively, said control value corresponds to the mean value of normalized (relative) mean value of NOX5 and/or ROCK1 expression observed in a non-tumoral tissue of the patient.
The comparison step may be carried out manually or computer assisted.
Expression of the predictive biomarkers NOX5 and/or ROCK1 can be quantified by determining gene or protein expression of such predictive biomarkers in the biological sample of the tumor of a subject. The quantification may be relative (by comparing the amount of a biomarker to a control with known amount of biomarker for example and detecting “higher” or “lower” amount compared to that control) or more precise, at least to determine the specific amount relative to a known control amount.
The terms “nucleic acid” and “polynucleotide” are used interchangeably and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides can have any three-dimensional structure and may perform any function. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, messenger RNA (mRNA), cDNA, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can be further modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of this invention that is a polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form.
A “gene” refers to a polynucleotide containing at least one open reading frame
(ORF) that is capable of encoding a particular polypeptide or protein after being transcribed and translated. A polynucleotide sequence can be used to identify larger fragments or full-length coding sequences of the gene with which they are associated. Methods of isolating larger fragment sequences are known to those of skill in the art. “Gene expression”, “gene product” or “expression” are all used herein interchangeably and refer to the nucleic acids or amino acids (e.g., peptide or polypeptide) generated when a gene is transcribed and translated, cDNA or RNA sequence of the biomarker; biomarker gene expression, biomarker protein expression, biomarker mRNA expression; functional effect of the biomarker protein, functional effect of the biomarker gene, cDNA or mRNA, protein, cDNA, gene or mRNA activity.
In a particular embodiment “expression level” “gene expression”, “gene product” or “expression” denotes mRNA expression, cDNA expression, protein transcription and protein expression.
The term “polypeptide” is used interchangeably with the term “protein” and in its broadest sense refers to a compound of two or more subunit amino acids. The subunits can be linked by peptide bonds.
Such quantification methods may alternatively include detection and quantification of the corresponding gene expression level of said predictive biomarker which encompasses the quantification of corresponding mRNA of said predictive biomarker, for example by performing Real-Time quantitative PCR, as well as by using DNA microarrays, i.e. substrate onto which are bound nucleic acids, at defined position, that specifically hybridize with the cDNA corresponding to amplified mRNA of said predictive biomarker.
Typically, in specific embodiments, a mixture of transcribed polynucleotides (mRNA) obtained from the biological sample of the patient is subjected to reverse transcription and quantitative amplification. Said cDNA or mRNA may be detected by in vitro techniques either by stringent hybridization to DNA microarrays or Northern blots.
In any cases, a general principle of such detection and quantification assays involve preparing a sample or reaction mixture that may contain a predictive biomarker and a probe under appropriate conditions and for a time sufficient to allow the predictive biomarker and probe to interact and bind, thus forming a complex that can be detected (and quantified) in the reaction mixture.
These detection and/or quantification assays of a biomarker can be conducted in a variety of ways. Appropriate conditions to the particular assay and components thereof will be well known to one skilled in the art.
In a particular embodiment, the level of predictive biomarker mRNA can be determined both by in vitro formats in a biological sample using methods known in the art.
Specific methods include without limitations PCR, RT-PCR, RT-qPCR or Northern blot.
Expression level of the biomarker can also be determined by examining protein expression or the protein product of at least one of the predictive biomarkers. Determining the protein level involves measuring the amount of any immunospecific binding that occurs between an antibody that selectively recognizes and binds to the polypeptide of the biomarker in a sample obtained from a patient and comparing this to the amount of immunospecific binding of at least one biomarker in a control sample. The amount of protein expression of the biomarker can be increased or reduced when compared with control expression.
Various methods are known in the art for detecting protein expression levels in such biological samples, including various immunoassays methods. They include but are not limited to radioimmunoassays, ELISA (enzyme linked immunosorbent assays), “sandwich” immunoassays, immunoradiometric assays, in situ immunoassays (using e.g., colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assays, immunofluorescent assays, flow cytometry, immunohistochemistry, confocal microscopy, enzymatic assays, surface plasmon resonance and PAGE-SDS. NOX5 or ROCK1 elisa kits are commercially available.
Alternatively, the enzymatic activity of NOX1 and/or ROCK1 activity may be measured as a predictive biomarker, using appropriate enzymatic assays. A rock1 kinase assay is available for example from PROMEGA (ADP-Glo™ Kinase Assay).
Administering the Nanoparticles to the Subject to be Treated
The method of the present invention comprises a step of administering an efficient amount of a suspension of the nanoparticles to the tumor of the subject.
The nanoparticles can be administered to the subject using different possible routes such as local (intra-tumoral (IT), intra-arterial (IA)), subcutaneous, intravenous (IV), intradermic, airways (inhalation), intra-peritoneal, intramuscular, intra-thecal, intraocular or oral route.
In specific embodiments, the nanoparticles are administered intravenously, and the nanoparticles are advantageously targeted to the tumors, by passive targeting, for example by enhanced permeability and retention effect.
Repeated injections or administrations of nanoparticles can be performed, when appropriate. In one embodiment, the nanoparticles is administered to the patient an amount so that, at the time of irradiation of the tumor, the high-Z element (e.g. gadolinium) concentration in the tumor, is between 0,1 and 10 μg high-Z element.g−1.
In a specific embodiment, a single dose between 15 mg/kg and 100 mg/kg of nanoparticles (for example the coreless ultrafine nanoparticles with chelates of gadolinium) is injected intravenously in a subject.
In a specific embodiment, the nanoparticles is administered to the tumor of the patient so that, the nanoparticle is present in the irradiated region of the tumor at a concentration between 0,1 mg/l and 1 g/l, preferably between 0,1 and 100 mg/l.
Since the effect of induction of senescence and/or cellular cannibalism is mediated by NOX5 and/or ROCK1 activity, it may be advantageous to further administer an enhancer or a modulator agent of NOX5 and/or ROCK1 activity to the patient.
Accordingly, in a specific embodiment of the method of treatment, the method of treatment further includes a step of administering an enhancer or a modulator agent of NOX5 and/or ROCK1 activity, prior to, or concomitantly, or after the exposure step to ionizing radiations. As used herein, an enhancer agent of NOX5 and/or ROCK1 activity, refers to a compound or drug or combination of compounds or drugs that can increase NOX5 and/or ROCK1 activity in vivo, for example, in the tumor tissue of the patient. Such enhancer agent may be a direct activator of the oxidase activity of NOXS or kinase activity of ROCK1 or an indirect enhancer, acting for example downstream of the signaling pathways of NOX5 or ROCK1 respectively.
Examples of such enhancer agents of NOX5 include ciplatin, calcium influx, phorbol myristate acetate, Angiotensin II and endothelin-1.
As used herein, a modulator agent of NOX5 and/or ROCK1 activity, refers to a compound or drug or combination of compounds or drugs that can increase, decrease or abolish NOX4 and/or ROCK1 activity in vivo, for example, in the tumor tissue of the patient. Such modulator agent may be a direct activator or inhibitor of the oxidase activity of NOX5 or kinase activity of ROCK1 or an indirect enhancer or inhibitor, acting for example downstream of the signaling pathways of NOX5 or ROCK1 respectively.
The inventors have further found that the combined effect or ionizing radiations and the nanoparticles may induce an immune response mediated by NOX5 activity, against the tumor cells. Such response may be directed to the cells of the irradiated tumors, or to other tumor cells within the patient.
It may be therefore advantageous to increase such immune response for example by combining the method of treatment with an immunotherapeutic treatment. Accordingly, in a specific embodiment, the method of the present invention further comprises a step of administering an immunotherapeutic agent prior to, or concomitantly, or after the exposure step to ionizing radiations, to further enhance the immune response in addition or synergy to the immune response induced by the combined effect of ionizing radiations and nanoparticles. Typically, said immunotherapeutic drug is selected among the immune checkpoint inhibitors. Immune checkpoint inhibitors are described for example in Parldoll D M Nat Rev Cancer 12(2012):252-264 and Herrera F G et al CA Cancer J Clin. 67(2017):65-85. doi: 10.3322/caac.21358. These include for example PD1/PDL1 inhibitors, CTLA4 inhibitors, and more specifically, anti-PD1 or anti-PDL1 antibodies and/or anti-CTLA4 antibody.
One of the major finding of the inventors is that the combined effect of nanoparticles and ionizing radiations induce cell death of tumors by a mechanism that is not related to apoptosis (non-cell autonomous cell death mechanism). Therefore, the method of treatment of the present invention may be more particularly suitable for treating tumors that have been shown to be resistant to usual chemotherapeutic treatments inducing apoptosis of tumor cells. Such usual chemotherapeutic treatment includes in particular cisplatinum and derivatives, 5 Fluor-uracile, taxanes, and EGFr inhibitors.
The method of treatment of the invention may further comprise a step of administering a senescence inducer agent. Such senescence inducer agent may advantageously enhance senescence in addition or synergy to the senescence induced by the combined effect of ionizing radiations and the nanoparticles. In specific embodiment, said senescence inducer agent is selected among the chemotherapeutic agents, known to induce senescence, including without limitation:
Actinomycin, all-trans retinoic, acid Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyureal, darubicin, Imatinib, Irinotecan, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Teniposide, Tioguanine, Topotecan, Valrubicin, Vemurafenib, Vinblastine, Vincristine, Vindesine.
Exposing the Tumor to Ionizing Radiations
The nanoparticles herein described will be used to treat tumors where radiotherapy is a classical treatment or is the most appropriate treatment or could be indicated.
Radiation therapy or radiotherapy is the medical use of irradiation -i.e. ionizing radiation- as part of cancer treatment to control malignant cells. It is used as palliative treatment or as therapeutic treatment. Radiotherapy is accepted as an important standard therapy for treating various types of cancers.
As used herein, the term “radiotherapy” is used for the treatment of diseases of oncological nature with irradiation corresponding to ionizing radiation. Ionizing radiation deposits energy that injures or destroys cells in the area being treated (the target tissue) by damaging their genetic material, making it impossible for these cells to continue to grow.
In specific embodiment, the method of the invention comprises exposing the tumor comprising the nanoparticles to an efficient dose of ionizing radiations, wherein said ionizing radiations are photons, e.g. X-rays. Depending on the amount of energy they possess, the rays can be used to destroy cancer cells on the surface of or deeper in the body. The higher the energy of the X-ray beam, the deeper the X-rays can go into the target tissue. Linear accelerators and betatrons produce X-rays of increasingly greater energy. The use of machines to focus radiation (such as X-rays) on a cancer site is called external beam radiotherapy. In an alternative embodiment of the method of treatment according to the invention, gamma rays are used. Gamma rays are produced spontaneously as certain elements (such as radium, uranium, and cobalt 60) release radiation as they decompose, or decay.
Ionizing radiations are typically of 2keV to 25000 keV, in particular of 2 keV to 6000 keV (i.e. 6 MeV) or of 2 keV to 1500 keV (such as cobalt 60 source).
A person of ordinary skill in the radiotherapy art knows how to determine an appropriate dosing and application schedule, depending on the nature of the disease and the constitution of the patient. In particular, the person knows how to assess dose-limiting toxicity (DLT) and how to determine the maximum tolerated dose (MTD) accordingly.
The amount of radiation used in photon radiation therapy is measured in gray (Gy), and varies depending on the type and stage of cancer being treated. For curative cases, the typical dose for a solid epithelial tumor ranges from 60 to 80 Gy. Many other factors are considered by radiation oncologists when selecting a dose, including whether the patient is receiving chemotherapy, patient co-morbidities, whether radiation therapy is being administered before or after surgery, and the degree of success of surgery.
The total dose is typically fractionated (spread out over time). Amount and schedules (planning and delivery of ionizing radiations, fraction dose, fraction delivery schema, total dose alone or in combination with other anti-cancer agents etc) is defined for any disease/anatomical site/disease stage patient setting/age and constitutes the standard of care for any specific situation.
A typical conventional fractionation schedule for adults may be 1.8 to 2 Gy per day, five days a week, for example for 5 to 8 consecutive weeks.
Considering the combined effect of nanoparticles and ionizing radiations according to the present method obtained with high dose of ionizing radiations, in one specific embodiment, the dose of ionizing radiations exposed to the tumor of the patient is advantageously hypo fractionated. For example, a dose per fraction of at least 3 Gy, and for example between 3 Gy and 9 Gy, or between 5 and 7 Gy is exposed to the tumor of the patient and radiation total dose is delivered in few fractions (typically, but not necessarily no more than 10 fractions).
The inventors have established that the combined treatment with the nanoparticles and radiotherapy enables to induce an effect also on tumor cells which have not been irradiated, in particular via induction of cellular senescence, cellular cannibalism and/or immune response on such cells.
According to the advantageous effect, the treatment thus may typically enable enhancement of senescence by a factor of at least 10%, 20%, 30%, 40% or at least 50%, as compared to senescence induced by the same exposure to ionizing radiations but without the presence of nanoparticles.
According to the advantageous effect, the treatment thus may also typically enable enhancement of cellular cannibalism by a factor of at least 10%, 20%, 30%, 40% or at least 50%, as compared to cellular cannibalism induced by the same exposure to ionizing radiations but without the presence of nanoparticles.
Therefore, in one embodiment, the volume of the tumors exposed to ionizing radiations is smaller than the total volume to be treated, for example at least 10%, 20%, 30%, 40%, or at least 50% smaller (in volume).
Additionally, in certain embodiments, the method enables the treatment of tumors located outside of the region exposed to ionizing radiations.
The nanoparticles may be administered e.g. , 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours), prior to the administration of the first irradiation of radiotherapy, to the subject with the tumor to be treated.
Other aspects and advantages of the method of the invention will become apparent in the following examples, which are given for purposes of illustration only.
Materials and Methods
Cells, Reagents and Gadolinium-Based Nanoparticles
Colorectal carcinoma (p53+/+, p53R248W/+ and p53R248/−) HCT116 cells were maintained in McCoy's 5A medium (Life Technology) supplemented with 10% heat-inactivated fetal bovine serum (Hycultec GmbH), 2 mM L-glutamine and 100 IU/mL penicillin-streptomycin (Life technology). Human colon carcinoma mutant HCT116 p53R248W/−/ , p53R248W/+ and HCT116 p53+/+ were obtained from Dr. Christophe Bourdon. The benzyloxycarboxyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD-fmk) was obtained from Bachem. The ROCK1 inhibitor (Y27632) and the N-acetylcysteine (NAC) were from Sigma and the Manganese (III)-tetrakis(4-benzoic acid) porphyrin (MnTBAP) from Merck chemicals. Gadolinium-based Nanoparticle (GdBN) were obtained from NH TherAguix.
RNA—Mediated Interference
The small interfering RNAs (siRNAs) specific for ROCK1 (siRNA-1 ROCK1: 5′ GCC GCC GGG ACC CAA CUA U 3′; siRNA-2 ROCK1: 5′ GGA AUC CAG UUG AAU ACA A 3′) and control siRNA (siRNA-1 Co.:5′ GCC GGU AUG CCG GUU AAG U 3′) were obtained from Sigma. The SMARTpool siGENOME NOX5 siRNA (siRNA NOXS) (D-010195-05) contains 4 siRNA (siRNA-1 : 5′ GGA GCA AGG UGU UCC AGA A 3′; siRNA-2: 5′ CUA UAG ACC UGG UGA CUA C 3′; siRNA-3 : 5′ GCU UAU GGG CUA CGU GGU A 3′ and siRNA-4: 5′ CCU UCU UUG CAG AGC GAU U 3′). The control siGENOME Non-Targeting siRNA (indicated as siRNA-2 Co.) is a pool of four on-target plus non-targeting siRNAs (D-001206-13-05). SMARTpool siGENOME NOX5 siRNA and siGENOME Non-Targeting siRNA Pool #1 were purchased from Dharmacon. For RNA interference, HCT116 cells were seeded (5.0×105 cells/2 mL/well in 6-well plate) 48 hours before siRNAs transfection. Then, cells were transfected with 10 nM siRNAs using Lipofectamine RNAi max (#13778150, Life technologies) according to the manufacturer's instructions and incubated at 37° C. for 24h before subsequent experiments.
Irradiation
HCT116 cells were seeded in 6-well plates and incubated at 37° C. during 1 hour with indicated concentrations of GdBN. Then, cells were irradiated with X-ray irradiator (1 Gy/min, 200 keV, 15 mA, 2 mm copper thickness, X-RAD 320, Precision X-Ray) or with gamma-ray irradiator (IBL-637, Cs137, 1 Gy/min, gamma CIS-BioInternational, IBA, Saclay, France). Cells were harvested at indicated time points after irradiation for subsequent experiments.
Immunofluorescence and Flow Cytometry
Cellular cannibalism was determined as previously described13. Briefly, treated cells were stained with 10 μM of 5-(and-6)-(((4-Chloromethyl)Benzoyl)Amino)Tetramethylrhodamine (Cell Tracker Orange CMTMR, Invitrogen) and untreated cells were stained with 10 μM of 5-chloromethylfluorescein diacetate (Cell tracker Green CMFDA, Invitrogen). Cells are then co-cultured for the indicated time, in presence of the pharmacological inhibitor of ROCK, Y27632 (30 μM, TOCRIS) or the pan-caspase inhibitor, zVAD-fmk (100 μM, Calbiochem). For specific subcellular staining of the cyclin-dependent kinase inhibitor p21 on single and cannibal cells, cells were fixed in 4% paraformaldehyde/ phosphate-buffered saline (PBS) for 10 minutes, permeabilized in 0,3% Triton X-100 (Sigma) in PBS and incubated with 5% FCS-PBS for 1 hour. Rabbit antibody against human p21 (form Cell Signaling Technology, #2947) was used for immunodetection in PBS containing 1 mg/ml BSA and revealed with goat anti-rabbit IgG conjugated to Alexa 488 fluorochrome from Invitrogen. Cells were counterstained with Hoechst 33342 (Invitrogen) and analyzed by fluorescent confocal microscopy on a Zeiss LSM510 or by fluorescent microscopy on a LEICA DMi8 using a 63× objective. To detect the induction of cell death by flow cytometry, cells were stained with 3,3′-dihexyloxacarbocyanine, DIOC6(3) at 40 nM and propidium iodide at 2 μg/mL (Invitrogen, Molecular probes, OR, USA) for 30 min at 37° C. and 5% CO2. Cytofluorometric determinations were carried out on Guava EasyCyte (Millipore EMD) and data were analyzed by means with Incyte software (Millipore). Cell cycle distributions were assessed with 10 μg/ml of Hoechst 33342 (Invitrogen), as previously described14. Cell fluorescence was quantified using LSR II™ flow cytometer (Becton-Dickinson). Fluorescence histograms were analyzed with Kaluza software version 1.5.
Detection of Senescence Associated β-Galactosidase
At the indicated time, cells were fixed and stained using the senescence β-galactosidase staining kit (Cell signaling technologies) as previously described13.
Immunoblotting
Total cell lysates were prepared in lysis buffer (0,1% NP40 ; 200 mM HEPES ; 100 mM KCl; 1 mM EDTA; 1% Glycerol final concentration) supplemented with proteases and phosphatases inhibitors cocktail (EDTA-free inhibitors, Roche-diagnostics, Meylan, France). Protein extracts were quantified using the Bradford assay (Bio-Rad Laboratories, Hercules, Calif., USA). Protein extracts (20-40 μg) were run onto 4-12% NuPAGE Bis-tris gel (Invitrogen) and transferred onto nitrocellulose membrane at 4° C. After blocking, membranes were incubated overnight at 4° C. with primary antibodies according to the manufacturer's instructions: p21WAF1/CIP1 (Cell signaling #2947); NOX-5 (Abcam #191010) ; cleaved caspase-3 (Cell signaling #9664) ; MLC2S19* (Cell signaling #3671) or MLC2 (Cell signaling #8505). Horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit (Southern Biotechnology) antibodies were then incubated during 1 hour and revealed with the enhanced chemiluminescence prime detection (Amersham, GE-Healthcare) using direct chemiluminescence image scanning (G :BOX Syngene). GAPDH (#MAB374, EMD Millipore) was used as loading control.
Detection of ROS Production.
Cells were seeded on cover glass dishes (World Precision Instruments). Intracellular ROS levels were evaluated using the fluorescent probe (2,7-dichlorohydro-fluorescein diacetate (H2DCFDA) according to the manufacturer's instructions (Invitrogen). Cells were counterstained with Hoechst 33342 (Invitrogen) and analyzed by fluorescent microscopy (Leica DMi8 using a 63× objective).
RNA Interference.
The NOX5 silenced HCT116 clone was performed using a pool of three specific small hairpin RNAs (shRNA) against NOX5 gene expressed in GIPZ lentiviral vector. shRNA specific for NOX5 (sh1NOX5 (clone ID, V3LHS 353964: 5′ CTTGGACACCTTCGATCCA3′; sh2NOX5 (clone ID, V2LHS 136069): 5′ TAGAACACCTCAAAGTGGC3′; sh3NOX5 (clone ID, V2LHS 136068): 5′ ACAAAGTTCACAGTGTGAG3′) and control shRNA (shControl: 5′ GCCGGUAUGCCGGUUAAGU3′) were purchased from Dharmacon. The control clone was performed using the Non-silencing GIPZ control lentiviral vector (clone ID: RHS4346, Dharmacon).
Quantitative Real-Time RT-PCR
For the detection of NOX5 mRNA, we used the predesigned Applied Biosystems probes for NOX 5 gene (Hs00225846_m1) and GAPDH (Hs02758991_g1) (for normalization). These probes were included in the premade TaqMan Gene expression mixes obtained from Applied Biosystems. The results were analysed with the cycle threshold method (CT) and each sample was normalized to the quantity of endogenous GAPDH mRNA.
Tumor Growth in Immunodeficient Mice
Human colorectal HCT116 cells that have been depleted (shNOX5) or not (shControl) for NOX5 were pre-treated with 1.2 mM of GdBN during 1 hour at 37° C. and irradiated with one single dose of 6 Gy X-rays (XR). Then, 2.5 106 shControl or shNOX5 HCT116 cells cells were implanted in 6 week-old Swiss nude mice (Charles River Laboratories) and tumor growths were monitored in a time-dependent manner. The experiments were not randomized, performed in compliance with the EU Directive 63/2010 and approved by Ethical Committee at Gustave Roussy Cancer Campus (CEEA IRCIV/IGR n° 26).
Statistical Analysis
No statistical method was used to predetermine the sample size. Statistical significances were determined using the one-way ANOVA test. Statistically significant values are reported in figure legends. All experiments were independently performed at least three times. Data are expressed as mean±SEM. GraphPad Prism version 6.0b (GraphPad Software) was employed to perform statistical analysis.
Results
The combination of gadolinium-based nanoparticles with ionizing radiation induces cellular senescence
As we previously reported,13,14 cancer cells are eliminated after ionizing radiation through distinct lethal modalities (including NCAD or CAD deaths) that may be induced simultaneously to cellular senescence. To determine the biological effects of the irradiation of cancer cells in presence of gadolinium-based nanoparticles, we first analyzed the ability of this treatment to induce the senescence of cancer cells. Thus, human colorectal HCT116 cells were pre-treated with 1.2 mM of gadolinium-based nanoparticles (GdBN) during 1 hour and then, irradiated with one single dose of 6 Gy X-rays (XR). After 2 days, the cytoplasmic senescence-associated β-galactosidase (SA-β-Gal) activity, the expression of the cyclin-dependent kinase inhibitor protein p21 and the cell cycle progression of treated HCT116 cells were analyzed. We detected a significant increase of the frequency of SA-β-Gal+ cells after the treatment of HCT116 cells with XR, as compare to control, and also paid a particular attention to the fact that the combination of GdBN+XR significantly increases the number of SA-β-Gal+ cells detected after treatment with XR (
The Gadolinium-Based Nanoparticles Favors the Cellular Cannibalism of Irradiated Cancer Cells
To further identify lethal processes that are induced by the combined treatment of cancer cells with GdBN and XR, we determined the ability of this treatment to induce cell-autonomous and non-cell autonomous deaths. In this context, as previously described13, 14, we first performed co-cultures between untreated HCT116 cells that have been labeled with 5-(and-6)-(((4-chloromethyl)benzoyl)amino) tetramethylrhodamine (CMTMR, red) fluorescent vital probe and isogenic HCT116 cells that have been labeled with 5-chloromethylfluorescein diacetate (CMFDA, green) fluorescent vital probe, and irradiated with different doses in presence (or in absence) of indicated concentrations of GdBN. After 24 hours of co-culture, cell fates of CMFDA+ cells and CMTMR+ cells were analyzed for cell engulfment. Confocal analysis showed that during co-cultures of irradiated (XR) or GdBN+XR-treated CMTMR+ HCT116 cells with untreated CMFDA+ HCT116 cells (
The Activation of ROCK1 Kinase is Required for the Live Cell Engulfment Detected after GdBN+XR Treatment
To precise the molecular mechanisms involved in the cellular cannibalism that we described above, we then studied the signaling pathways that are associated with the live cell engulfment of neighboring cancer cells. We first revealed that the cellular engulfment that was observed after XR or GdBN+XR treatment, occurred in absence of cell death induction (as revealed by the absence of pro-apoptotic cleavage of caspase-3 after XR or GdBN+XR treatment (
The degradation of Engulfed Cells Positively Correlates with the Senescence of Cannibal Cells
To determine the fate of both engulfed cells and cannibal cells detected after XR or GdBN+XR treatment, we detected through fluorescence microscopy, the presence of chromatin condensation and nuclear fragmentation in the nuclei of engulfed HCT116 cells observed after 24 hour co-culture of HCT116 cells that were irradiated with 6 Gy in presence (or in absence) of 1.2 mM GdBN was determined. We observed that all engulfed cells detected after the irradiation alone or after the irradiation of cancer cells in presence of GdBN, exhibited signs of target cell degradation (
GdBN+XR Mediated Senescence and Cellular Cannibalism are Controlled by a NADPH Oxidase 5 (NOX5)-Dependent ROS Production
Considering that the reactive oxygen species (ROS) production is one of the major cellular stresses involved in the induction of senescence after ionizing radiation17, we analyzed the ROS production after XR and GdBN+XR treatments. By detecting with fluorescence microscopy the conversion of the non-fluorescent dye 2,7-dichlorohydro fluorescein diacetate (H2DCFDA) into fluorescent 2,7-dichlorohydro fluorescein (DCF), we determined the ability of single cells and cannibal cells obtained after XR or GdBN+XR treatment to generate ROS. We observed that these treatments induced the production of ROS in both single and cannibal cells (
To determine whether the NADPH oxidases (NOX), which are the major intracellular sources of ROS production, may regulate these processes19,20, we determined whether the NADPH oxidase 5 (NOX5)—a NADPH oxidase that has been involved in the death of irradiated human primary fibroblasts21—may participate to the production of ROS. Thus, we evaluated the effects of NOX5 depletion on the ROS production, the p21 expression, the SA-β-Galactosidase activity and the cellular cannibalism that are detected after the treatment of HCT116 cells with XR or ΓδBN+ΞP (
NADPH Oxidase 5 (NOX5) Inactivation Enhances Tumor Suppression Elicited by XR and GdBN+XR Treatments.
To characterize the impact of NOX5 inactivation on tumor growth, human colorectal HCT116 cells that have been depleted (shNOX5) or not (shControl) through RNA interference using short hairpin RNA (
Imaging and radiation effects of gold nanoparticles in tumour cells. Sci Rep 2016, 6: 19442.
| Number | Date | Country | Kind |
|---|---|---|---|
| 17305869.4 | Jul 2017 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2018/068099 | 7/4/2018 | WO | 00 |
